Menu Search
Equities

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

600332:SHH

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)24.61
  • Today's Change0.00 / 0.00%
  • Shares traded5.06m
  • 1 Year change-20.84%
  • Beta0.9587
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy1
Outperform1
Hold0
Sell2
Strong Sell0

Share price forecast in CNY

The 3 analysts offering 12 month price targets for Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd have a median target of 23.60, with a high estimate of 36.10 and a low estimate of 18.80. The median estimate represents a -4.41% decrease from the last price of 24.69.
High46.2%36.10
Med-4.4%23.60
Low-23.9%18.80

Dividends in CNY

In 2023, Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd reported a dividend of 0.75 CNY, which represents a 2.32% increase over last year. The analyst covering the company expects dividends of 0.68 CNY for the upcoming fiscal year, a decrease of 9.21%.
Div growth (TTM)2.32%
More ▼

Earnings history & estimates in CNY

On Aug 30, 2024, Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd reported 2nd quarter 2024 earnings of 0.364 per share.
The next earnings announcement is expected on Oct 28, 2024.
Average growth rate+126.14%
Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd reported annual 2023 earnings of 2.50 per share on Mar 15, 2024.
Average growth rate+6.98%
More ▼

Revenue history & estimates in CNY

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited had revenues for the full year 2023 of 75.52bn. This was 6.68% above the prior year's results.
Average growth rate+4.03%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.